EDIT – Editas Medicine, Inc.
Float Short %
8.77
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
0.38
EPS Last/This Y
0.88
EPS This/Next Y
1.04
Price
2.68
Target Price
4
Analyst Recom
2.43
Performance Q
23.39
Relative Volume
0.46
Beta
2.13
Ticker: EDIT
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | EDIT | 3.04 | 0.06 | 0.04 | 59475 |
| 2025-08-18 | EDIT | 2.73 | 0.05 | 0.31 | 47288 |
| 2025-08-19 | EDIT | 2.64 | 0.06 | 0.75 | 47834 |
| 2025-08-20 | EDIT | 2.66 | 0.06 | 0.06 | 48083 |
| 2025-08-21 | EDIT | 2.74 | 0.06 | 0.33 | 47936 |
| 2025-08-22 | EDIT | 2.8 | 0.06 | 0.00 | 48044 |
| 2025-08-25 | EDIT | 2.71 | 0.07 | 0.83 | 45311 |
| 2025-08-26 | EDIT | 2.73 | 0.07 | 0.61 | 45276 |
| 2025-08-27 | EDIT | 2.67 | 0.07 | 0.02 | 45279 |
| 2025-08-28 | EDIT | 2.65 | 0.07 | 0.02 | 45324 |
| 2025-08-29 | EDIT | 2.57 | 0.07 | 0.33 | 45277 |
| 2025-09-02 | EDIT | 2.47 | 0.07 | 0.09 | 45885 |
| 2025-09-03 | EDIT | 2.5 | 0.07 | 0.14 | 46432 |
| 2025-09-04 | EDIT | 2.52 | 0.07 | 0.62 | 46418 |
| 2025-09-05 | EDIT | 2.76 | 0.07 | 0.13 | 46516 |
| 2025-09-08 | EDIT | 2.79 | 0.07 | 0.11 | 46712 |
| 2025-09-09 | EDIT | 2.76 | 0.07 | 0.03 | 46829 |
| 2025-09-10 | EDIT | 2.56 | 0.07 | 0.21 | 46747 |
| 2025-09-11 | EDIT | 2.7 | 0.07 | 0.40 | 46766 |
| 2025-09-12 | EDIT | 2.68 | 0.08 | 0.44 | 47102 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | EDIT | 3.04 | 53.7 | - | -1.84 |
| 2025-08-18 | EDIT | 2.73 | 60.2 | - | -2.01 |
| 2025-08-19 | EDIT | 2.63 | 53.7 | - | -2.01 |
| 2025-08-20 | EDIT | 2.67 | 53.7 | - | -2.01 |
| 2025-08-21 | EDIT | 2.74 | 53.7 | - | -2.01 |
| 2025-08-22 | EDIT | 2.80 | 49.7 | - | -2.03 |
| 2025-08-25 | EDIT | 2.71 | 49.7 | - | -2.03 |
| 2025-08-26 | EDIT | 2.73 | 49.7 | - | -2.03 |
| 2025-08-27 | EDIT | 2.67 | 49.7 | - | -2.03 |
| 2025-08-28 | EDIT | 2.64 | 49.7 | - | -2.03 |
| 2025-08-29 | EDIT | 2.57 | 49.7 | - | -2.03 |
| 2025-09-02 | EDIT | 2.47 | 49.7 | - | -2.03 |
| 2025-09-03 | EDIT | 2.50 | 49.7 | - | -2.03 |
| 2025-09-04 | EDIT | 2.52 | 49.7 | - | -2.03 |
| 2025-09-05 | EDIT | 2.76 | 49.7 | - | -2.02 |
| 2025-09-08 | EDIT | 2.79 | 51.4 | - | -2.00 |
| 2025-09-09 | EDIT | 2.76 | 51.4 | - | -2.00 |
| 2025-09-10 | EDIT | 2.57 | 51.4 | - | -2.00 |
| 2025-09-11 | EDIT | 2.71 | 51.4 | - | -2.00 |
| 2025-09-12 | EDIT | 2.68 | 51.4 | - | -2.00 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | EDIT | -5.36 | -11.97 | 8.81 |
| 2025-08-18 | EDIT | -5.36 | -13.87 | 8.81 |
| 2025-08-19 | EDIT | -5.36 | -13.87 | 8.81 |
| 2025-08-20 | EDIT | -5.36 | -13.87 | 8.81 |
| 2025-08-21 | EDIT | -5.36 | -13.87 | 8.81 |
| 2025-08-22 | EDIT | -5.36 | -13.87 | 8.81 |
| 2025-08-25 | EDIT | -5.36 | -5.90 | 8.81 |
| 2025-08-26 | EDIT | -5.36 | -5.90 | 8.81 |
| 2025-08-27 | EDIT | -5.36 | -5.90 | 9.21 |
| 2025-08-28 | EDIT | -5.36 | -5.90 | 9.21 |
| 2025-08-29 | EDIT | -5.36 | -5.90 | 9.21 |
| 2025-09-02 | EDIT | -5.36 | -6.00 | 9.21 |
| 2025-09-03 | EDIT | -5.36 | -6.00 | 9.21 |
| 2025-09-04 | EDIT | -6.10 | -6.00 | 9.21 |
| 2025-09-05 | EDIT | -6.10 | -6.00 | 9.21 |
| 2025-09-08 | EDIT | -3.45 | -6.01 | 9.21 |
| 2025-09-09 | EDIT | -3.45 | -6.01 | 9.21 |
| 2025-09-10 | EDIT | -3.45 | -6.01 | 9.21 |
| 2025-09-11 | EDIT | -3.45 | -6.01 | 8.77 |
| 2025-09-12 | EDIT | -3.45 | -6.01 | 8.77 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.63
Avg. EPS Est. Current Quarter
-0.36
Avg. EPS Est. Next Quarter
-0.25
Insider Transactions
-3.45
Institutional Transactions
-6.01
Beta
2.13
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
7
Fair Value
Quality Score
4
Growth Score
27
Sentiment Score
86
Actual DrawDown %
97.3
Max Drawdown 5-Year %
-98.9
Target Price
4
P/E
Forward P/E
PEG
P/S
6.22
P/B
12.25
P/Free Cash Flow
EPS
-2.85
Average EPS Est. Cur. Y
-2
EPS Next Y. (Est.)
-0.96
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-608.88
Relative Volume
0.46
Return on Equity vs Sector %
-1259.2
Return on Equity vs Industry %
-1246.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.17
EBIT Estimation
Editas Medicine, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 246
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
stock quote shares EDIT – Editas Medicine, Inc. Stock Price stock today
news today EDIT – Editas Medicine, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EDIT – Editas Medicine, Inc. yahoo finance google finance
stock history EDIT – Editas Medicine, Inc. invest stock market
stock prices EDIT premarket after hours
ticker EDIT fair value insiders trading